Patterns and Presentation of Prostate Cancer in the Brong Ahafo Region of Ghana: A 6-Year Single Center Retrospective Study

Introduction: Prostate cancer is gradually reaching a very high incidence in Africa, especially in the Sub-Saharan region. Understanding the dynamics in occurrence of the disorder is one approach to developing effective public health programmes and interventions that will help curb the rising incidence. Objective: This study was aimed at providing comprehensive and credible data on prostate cancer by assessing the incidence, trend and presentation in the Brong Ahafo Region of Ghana. We sought to provide region-specific hardcore data that will help to assess the issue and provide remedies. Methodology: All prostate disease cases recorded from the year 2009 to 2018 were retrospectively reviewed. Subjects from 40 years and above were eligible for screening. Diagnostic and screening tools for prostate cancer at the study site include family history, serum prostate specific antigen (PSA) test, digital rectal examination, urological ultrasound scan and histopathology (biopsy). Age, PSA values and year of screening/diagnosis were also retrieved from patient folders for the study. Histological findings and parameters considered in the study included diagnosis, carcinoma grading, perineural invasion (PNI) and percentage of affected tissues (%TA). Results: Prostate cancer cases were 369, representing 36.4% of the 1,014 prostate diseases studied. The highest annual incidence was recorded in 2014 with 51 cases (13.8%). The ages of patients ranged from 46 to 101 years with a modal age range of 70 - 79 years and a mean ± SD of 72.2 ± 9.8. The mean PSA value recorded was 37.1ng/ml (±107.3) with predominance in the 11 - 20.9 ng/ml range. Majority of Group Grade 2-5 (79%) constituted progressive prostate cancer. There was no significant correlation (p = 0.091) between grade of prostate cancer and perineural invasion. Conclusion: There is a high incidence of prostate cancer in the Brong Ahafo Region of Ghana (32 per 100,000), predominantly advanced prostatic carcinoma. Reported cases also show high %TA (38.7%) and PNI (38.0%). Early screening for prostate diseases should be encouraged to avoid progression to advanced stage and public health interventions are needed to address some of these issues.

Download Full-text

The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study

Cancer Management and Research ◽

10.2147/cmar.s196286 ◽

2019 ◽

Vol Volume 11 ◽

pp. 6521-6529 ◽

Cited By ~ 1

Author(s):

Jiandong Liu ◽

Jinge Zhao ◽

Mengni Zhang ◽

Ni Chen ◽

Guangxi Sun ◽

...

Keyword(s):

Prostate Cancer ◽

Retrospective Study ◽

High Risk ◽

International Society ◽

Grading System ◽

Single Center ◽

High Risk Prostate Cancer ◽

Risk Prostate Cancer

Download Full-text

Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study

Journal of Nuclear Medicine ◽

10.2967/jnumed.120.241588 ◽

2020 ◽

Vol 61 (11) ◽

pp. 1602-1606 ◽

Cited By ~ 2

Author(s):

Thorsten Derlin ◽

Rudolf A. Werner ◽

Marcel Lafos ◽

Christoph Henkenberens ◽

Christoph A.J. von Klot ◽

...

Keyword(s):

Prostate Cancer ◽

Retrospective Study ◽

Neuroendocrine Differentiation ◽

Castration Resistant Prostate Cancer ◽

Single Center ◽

Radioligand Therapy ◽

Castration Resistant

Download Full-text

UP-2.130: Radical Prostatectomy for Clinically “Insignificant” Prostate Cancer: A Single-Center Retrospective Study

Urology ◽

10.1016/j.urology.2009.07.349 ◽

2009 ◽

Vol 74 (4) ◽

pp. S272

Author(s):

A. Ammani ◽

M. Abbar ◽

J. Eloundou ◽

A. Janane ◽

A. Ameur ◽

...

Keyword(s):

Prostate Cancer ◽

Retrospective Study ◽

Radical Prostatectomy ◽

Single Center ◽

Insignificant Prostate Cancer

Download Full-text

Statins Prevent Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Single-center Retrospective Study with a Median Follow-up of 51.20 Months

Research and Reports in Urology ◽

10.2147/rru.s258267 ◽

2020 ◽

Vol Volume 12 ◽

pp. 439-446

Author(s):

Roberto Jarimba ◽

João Pedroso Lima ◽

Miguel Eliseu ◽

João Carvalho ◽

Hugo Antunes ◽

...

Keyword(s):

Prostate Cancer ◽

Retrospective Study ◽

Radical Prostatectomy ◽

Biochemical Recurrence ◽

Single Center

Download Full-text

Abiraterone acetate in comparison to enzalutamide in African American patients with metastatic castrate-resistant prostate cancer: A single-center retrospective study.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e16547 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e16547-e16547

Author(s):

Mohammad Telfah ◽

Jeffrey M. Holzbeierlein ◽

Xinglei Shen ◽

Elizabeth Marie Wulff-Burchfield ◽

Rahul Atul Parikh

Keyword(s):

Prostate Cancer ◽

African American ◽

Retrospective Study ◽

Abiraterone Acetate ◽

Categorical Variables ◽

P Value ◽

Single Center ◽

Castrate Resistant Prostate Cancer ◽

Baseline Characteristics ◽

Castrate Resistant

e16547 Background: African American (AA) patients with metastatic castrate-resistant prostate cancer (mCRPC) represent a high-risk population with higher mortality. Recent data suggested that abiraterone acetate (AbA) is more effective in AA in comparison to white patients. There are limited data regarding enzalutamide (Enz) use in AAs. Here, we report the outcomes of (AbA) and (Enz) in AA patients with mCRPC at our center. Methods: A retrospective chart review included AA patients who had a diagnosis of mCRPC and were prescribed AbA and/or Enz at KUMC from 09-01-2008 through 09-01-2018. Patients were divided into two groups: those who started with AbA (abiraterone group) and those who started with Enz (enzalutamide group). Baseline characteristics were compared between the two groups using Fisher’s exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables. The primary outcome was progression-free survival (PFS) on AbA and Enz. PFS was measured from the time of starting either of the two medications to the time of formal relapse, defined by relapse that required therapy change or prostate-cancer-related death. A stepwise Cox proportional-hazard model was used to adjust for potential confounders. Results: During the study period, 28 AA patients with mCRPC received AbA and/or Enz. Twenty-two patients received AbA first, while six patients received Enz first. There were no significant differences in the baseline characteristics between the two groups. Median PFS for the abiraterone group was 24.3 months, while it was 11.7 months for the enzalutamide group, Log-rank test p-value 0.04). After adjusting for potential confounders, the hazard ratio of progression remained significant, favoring the abiraterone group, HR: 0.11, p-value 0.009. Median PFS on AbA after progression on previous Enz was 5.7 months, while it was 4.5 months for Enz after progression on previous AbA, p-value 0.2. Conclusions: In this single-center retrospective study, AA patients with mCRPC who were started on AbA rather than Enz had longer PFS. More studies are needed to understand the best sequence of the two medications in this population.

Download Full-text